Published in N Engl J Med on November 18, 1993
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol (1999) 9.11
Respiratory syncytial virus infection in adults. Clin Microbiol Rev (2000) 3.16
Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis (2004) 2.96
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res (2011) 2.51
Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev (2000) 2.38
A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med (2002) 2.34
Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med (2002) 2.32
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev (1999) 1.83
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A (2012) 1.80
Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol (2007) 1.77
Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev (2004) 1.67
Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child (2000) 1.60
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother (2009) 1.60
Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol (2001) 1.58
Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine (2013) 1.56
Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther (2011) 1.51
Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child (2004) 1.50
The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect (2007) 1.43
Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest (2005) 1.42
Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci U S A (1994) 1.40
Respiratory syncytial virus vaccines. Clin Microbiol Rev (1998) 1.38
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol (2001) 1.35
Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol (2003) 1.28
Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J Virol (1998) 1.27
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis (2010) 1.21
Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother (2004) 1.21
Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol (2010) 1.21
Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. PLoS One (2011) 1.18
Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J Virol (1999) 1.14
Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant (2013) 1.11
Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin Microbiol Rev (2008) 1.09
Respiratory syncytial virus genotypes and disease severity among children in hospital. Arch Dis Child (1997) 1.08
Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis (2010) 1.07
Respiratory viruses other than influenza virus: impact and therapeutic advances. Clin Microbiol Rev (2008) 1.05
Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine (2009) 1.05
Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent? Paediatr Child Health (1998) 1.04
An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. BMC Public Health (2011) 1.03
Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health (1999) 1.03
Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis (2011) 1.03
Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev (1999) 1.00
Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob Agents Chemother (2002) 0.98
Management of acute bronchiolitis. Arch Dis Child (1994) 0.98
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol (2010) 0.98
Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother (1994) 0.98
Use of palivizumab in children with congenital heart disease. Paediatr Child Health (2003) 0.97
Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev (1995) 0.97
Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review. Infect Dis Ther (2014) 0.96
Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother (2005) 0.96
A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis (2009) 0.96
Viral lower respiratory tract infection in infants and young children. BMJ (2003) 0.96
A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol (2013) 0.95
Human antibody neutralizes severe Fever with thrombocytopenia syndrome virus, an emerging hemorrhagic Fever virus. Clin Vaccine Immunol (2013) 0.95
Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res (2002) 0.94
Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States. Clin Diagn Lab Immunol (1996) 0.93
Influence of respiratory syncytial virus strain differences on pathogenesis and immunity. Curr Top Microbiol Immunol (2013) 0.93
Functional analysis of antibody responses of feedlot cattle to bovine respiratory syncytial virus following vaccination with mixed vaccines. Can J Vet Res (1997) 0.92
Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation. Virology (2009) 0.91
Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo. J Virol (2001) 0.91
Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics (2008) 0.91
Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob Agents Chemother (1999) 0.90
Human rhinoviruses in severe respiratory disease in very low birth weight infants. Pediatrics (2011) 0.90
Influence of common non-synonymous Toll-like receptor 4 polymorphisms on bronchopulmonary dysplasia and prematurity in human infants. PLoS One (2012) 0.87
A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo. J Virol (1998) 0.87
Differential gender response to respiratory infections and to the protective effect of breast milk in preterm infants. Pediatrics (2008) 0.87
Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates. Mol Ther Methods Clin Dev (2015) 0.86
Effects of aging on the adaptive immune response to respiratory virus infections. Aging health (2009) 0.86
Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response. J Virol (2013) 0.86
Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis (2006) 0.85
Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer (2008) 0.85
Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther (2009) 0.85
RSV infection among children born moderately preterm in a community-based cohort. Eur J Pediatr (2014) 0.85
Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV). Biologics (2007) 0.85
Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants. Clin Diagn Lab Immunol (1994) 0.84
Neutralization of respiratory syncytial virus after cell attachment. J Virol (1995) 0.84
Adherence to Immunoprophylaxis Regimens for Respiratory Syncytial Virus Infection in Insured and Medicaid Populations. J Pediatric Infect Dis Soc (2013) 0.83
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev (2017) 0.83
Clinically useful monoclonal antibodies in treatment. J Clin Pathol (2002) 0.82
An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology (2015) 0.82
Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Antimicrob Agents Chemother (1999) 0.81
Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine (2014) 0.80
Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant (2015) 0.80
Prospective evaluation of clinical scoring systems in infants with bronchiolitis admitted to the intensive care unit. Eur J Clin Microbiol Infect Dis (2012) 0.80
Impact of Placental Malaria and Hypergammaglobulinemia on Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea. J Infect Dis (2015) 0.80
Acute and Chronic Airway Disease After Human Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon hispidus). Comp Med (2015) 0.80
Respiratory syncytial virus immune globulin intravenous. Paediatr Child Health (1998) 0.79
Epidemiology of respiratory syncytial virus infection in preterm infants. Open Microbiol J (2011) 0.79
Why do viruses make infants wheeze? Arch Dis Child (1996) 0.79
Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol (2001) 0.79
Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses. J Virol (2016) 0.79
New Approaches for Immunization and Therapy against Human Metapneumovirus. Clin Vaccine Immunol (2015) 0.79
Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey. Korean J Pediatr (2011) 0.79
Safety, tolerability, and pharmacokinetics of the respiratory syncytial virus-prefusion F-targeting monoclonal antibody with an extended half-life, MEDI8897, in healthy adults. Antimicrob Agents Chemother (2016) 0.79
Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ (2009) 0.78
Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya. PLoS One (2016) 0.77
The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Clin Dev Immunol (2013) 0.77
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Human reovirus-like agent as the major pathogen associated with "winter" gastroenteritis in hospitalized infants and young children. N Engl J Med (1976) 7.57
Quality of hospital care for seriously ill children in less-developed countries. Lancet (2001) 7.08
A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med (1991) 5.76
Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med (1983) 5.41
Reoviruslike agent in stools: association with infantile diarrhea and development of serologic tests. Science (1974) 5.32
Clinically useful method for the isolation of respiratory syncytial virus. J Infect Dis (1975) 5.00
Epidemiology of human rotavirus Types 1 and 2 as studied by enzyme-linked immunosorbent assay. N Engl J Med (1978) 4.73
Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med (1994) 4.32
Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet (1993) 4.06
Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med (1982) 3.93
A nondefective (competent) adenovirus-SV40 hybrid isolated from the AD.2-SV40 hybrid population. Proc Natl Acad Sci U S A (1969) 3.81
Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother (1979) 3.61
Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med (1986) 3.43
Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis (1991) 3.27
Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol (1998) 3.06
Comparison of direct electron microscopy, immune electron microscopy, and rotavirus enzyme-linked immunosorbent assay for detection of gastroenteritis viruses in children. J Clin Microbiol (1981) 3.05
Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. V. Isolation of additional hybrids which differ in their simian virus 40-specific biological properties. J Virol (1973) 2.87
Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med (1994) 2.84
Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol (1988) 2.84
Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol (1985) (1986) 2.77
An unusual infection due to staphylococcus aureus. N Engl J Med (1971) 2.68
Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet (1997) 2.62
Comparative epidemiology of two rotavirus serotypes and other viral agents associated with pediatric gastroenteritis. Am J Epidemiol (1979) 2.56
Pediatric viral gastroenteritis during eight years of study. J Clin Microbiol (1983) 2.50
Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr (1976) 2.45
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol (1986) 2.43
Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis (1990) 2.41
Approaches to immunization of infants and young children against gastroenteritis due to rotaviruses. Rev Infect Dis (1980) 2.39
Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med (1982) 2.37
Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA (1985) 2.34
Low blood pressure and the risk of dementia in very old individuals. Neurology (2003) 2.30
Primary human herpesvirus 6 infection in young children. N Engl J Med (1992) 2.30
Epidemic measles in young adults. Clinical, epidemiologic, and serologic studies. Ann Intern Med (1979) 2.29
Atypical herpes simplex virus encephalitis diagnosed by PCR amplification of viral DNA from CSF. Neurology (1998) 2.26
Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Ann Intern Med (1978) 2.25
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis (1998) 2.24
Sales of nonprescription cold remedies: a unique method of influenza surveillance. Pediatr Res (1979) 2.22
Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med (2000) 2.15
Respiratory rate and pneumonia in infancy. Arch Dis Child (1991) 2.15
The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med (1981) 2.15
Sequential enteric illnesses associated with different rotavirus serotypes. Lancet (1978) 2.13
Rapid detection of respiratory syncytial virus with a monoclonal antibody. J Clin Microbiol (1983) 2.13
Evidence for HTLV-III infection in prostitutes in Tamil Nadu (India). Indian J Med Res (1987) 2.13
Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis (2000) 2.13
Rapid detection of respiratory syncytial virus in nasopharyngeal secretions by enzyme-linked immunosorbent assay. J Clin Microbiol (1985) 2.10
Prevalence of HIV infection in risk groups in Tamilnadu, India. Lancet (1987) 2.03
Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med (1983) 2.03
Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. VII. Characterization of the simian virus 40 RNA species induced by five nondefective hybrid viruses. J Virol (1973) 2.02
Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. J Pediatr (1978) 2.01
Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res (1976) 1.99
Respiratory syncytial virus infections within families. N Engl J Med (1976) 1.99
Adenoviruses and pediatric gastroenteritis. J Infect Dis (1985) 1.99
Vaccination strategies for mucosal immune responses. Clin Microbiol Rev (2001) 1.98
Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis (1997) 1.98
Virus-specific nucleic acids in SV40-exposed hamster embryo cell lines: correlation with S and T antigens. Proc Natl Acad Sci U S A (1969) 1.97
Missed opportunities for childhood vaccinations in office practices and the effect on vaccination status. Pediatrics (1993) 1.97
Standardized diagnosis of pneumonia in developing countries. Pediatr Infect Dis J (1992) 1.95
Human herpesvirus 7: antigenic properties and prevalence in children and adults. J Virol (1991) 1.93
Viral shedding patterns of children with influenza B infection. J Infect Dis (1979) 1.91
Use of subgenomic poliovirus DNA hybridization probes to detect the major subgroups of enteroviruses. J Clin Microbiol (1984) 1.90
Possible transmission by fomites of respiratory syncytial virus. J Infect Dis (1980) 1.87
Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis (1992) 1.86
Detection of parasite DNA in Chagas' heart disease. Lancet (1995) 1.86
Nosocomial respiratory syncytial virus infections. N Engl J Med (1975) 1.85
Modes of transmission of respiratory syncytial virus. J Pediatr (1981) 1.84
Neonatal respiratory syncytial virus infection. N Engl J Med (1979) 1.82
Children with influenza A infection: treatment with rimantadine. Pediatrics (1987) 1.80
Differentiation between two distinct classes of viruses now classified as human herpesvirus 6. Proc Natl Acad Sci U S A (1991) 1.79
Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol (1986) 1.79
Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis (2001) 1.79
Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis (2001) 1.78
Optochin resistance in Streptococcus pneumoniae: mechanism, significance, and clinical implications. J Infect Dis (2001) 1.78
Herpes simplex virus infection as a cause of benign recurrent lymphocytic meningitis. Ann Intern Med (1994) 1.77
Variable adherence of fimbriated Haemophilus influenzae type b to human cells. Infect Immun (1985) 1.77
Is underimmunization a marker for insufficient utilization of preventive and primary care? Arch Pediatr Adolesc Med (1995) 1.77
Immunization practices of pediatricians and family physicians in the United States. Pediatrics (1994) 1.75
Identification of infants unlikely to have serious bacterial infection although hospitalized for suspected sepsis. J Pediatr (1985) 1.73
Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr (1992) 1.70
Herpes simplex virus type 1 DNA in cerebrospinal fluid of a patient with Mollaret's meningitis. N Engl J Med (1991) 1.69
Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis (1995) 1.66
Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children. J Pediatr (1996) 1.65
Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr (1990) 1.64
The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses. J Pediatr (1980) 1.63
White matter abnormalities in mobility-impaired older persons. Neurology (2000) 1.61
Specificity of the blastogenic response of human mononuclear cells to herpesvirus antigens. Infect Immun (1978) 1.60
Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr (1990) 1.60
Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. 3. Base composition, molecular weight, and conformation of the Ad2+ND genome. J Virol (1971) 1.59
Somatic mutation and recombination test in Drosophila melanogaster. Environ Mutagen (1984) 1.56
Human reovirus-like agent infection. Occurrence in adult contacts of pediatric patients with gastroenteritis. JAMA (1977) 1.56
Influenza surveillance in community-dwelling elderly compared with children. Arch Fam Med (1997) 1.55
Stent implantation for relief of pulmonary artery stenosis: immediate and short-term results. Cathet Cardiovasc Diagn (1996) 1.55
Kawasaki syndrome: description of two outbreaks in the United States. N Engl J Med (1981) 1.52
Cellular localization of human herpesvirus-6 in the brains of children with AIDS encephalopathy. J Neurovirol (1995) 1.52
Proarrhythmia associated with cisapride in children. Pediatrics (1998) 1.52